Search This Blog

Wednesday, June 3, 2026

TransCode: completes Phase 1a of TTX-MC138, no dose-limiting toxicities, durable disease stabilization

 

TransCode Therapeutics completes Phase 1a trial of TTX-MC138 with no dose-limiting toxicities and durable disease stabilization

  • Company selected a 4.8 mg/kg recommended Phase 2a dose to support ongoing development in ctDNA-positive cancers.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)